$1,318.00
This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, Recent Events and Analyst Opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, Recent Events and Analyst Opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Surgery
8 Medical agents
10 EPIDEMIOLOGY
13 MARKETED DRUGS
15 PIPELINE DRUGS
19 RECENT EVENTS AND ANALYST OPINION
19 Orgovyx for Uterine Fibroids (March 24, 2021)
21 KEY UPCOMING EVENTS
22 KEY REGULATORY EVENTS
22 ObsEva’s Yselty Among 13 New Drugs On Track For EU Approval
22 Myovant/Pfizer Launch Myfembree With An Emphasis On Building Uterine Fibroid Awareness
22 Yes Or No? Decisions Due On New EU Drug Applications
23 PROBABILITY OF SUCCESS
24 LICENSING AND ASSET ACQUISITION DEALS
24 ObsEva And Theramex Team Up To Commercialize Linzagolix
25 REVENUE OPPORTUNITY
26 CLINICAL TRIAL LANDSCAPE
27 Sponsors by status
28 Sponsors by phase
30 BIBLIOGRAPHY
31 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of uterine fibroids, 2019–28
15 Figure 2: Overview of pipeline drugs for uterine fibroids in the US
15 Figure 3: Pipeline drugs for uterine fibroids, by company
15 Figure 4: Pipeline drugs for uterine fibroids, by drug type
16 Figure 5: Pipeline drugs for uterine fibroids, by classification
20 Figure 6: Orgovyx for Uterine Fibroids (March 24, 2021): Phase III – LIBERTY Withdrawal (w/Estradiol + Norethindrone Acetate)
21 Figure 7: Key upcoming events in uterine fibroids
23 Figure 8: Probability of success in the gynecology pipeline
26 Figure 9: Clinical trials in uterine fibroids
26 Figure 10: Top 10 drugs for clinical trials in uterine fibroids
27 Figure 11: Top 10 companies for clinical trials in uterine fibroids
27 Figure 12: Trial locations in uterine fibroids
28 Figure 13: Uterine fibroids trials status
29 Figure 14: Uterine fibroids trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of uterine fibroids, 2019–28
14 Table 2: Marketed drugs for uterine fibroids
17 Table 3: Pipeline drugs for uterine fibroids in the US
19 Table 4: Orgovyx for Uterine Fibroids (March 24, 2021)
25 Table 5: Historical global sales, by drug ($m), 2017–21
25 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!